CTEV
Claritev Corporation
CTEV trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over CTEV overall, supported by lower modeled downside and stronger fundamentals.
CTEV Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Weak |
CTEV's revenue and profitability are currently stable, but its cash flow and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CTEV PE Valuation
CTEV has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CTEV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect CTEV's revenue to grow, with its earnings and profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over CTEV on the outlook, with more favorable earnings and profitability expectations.
CTEV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$16.42 | +$4.87 |
| Q2 2026 | -$17.01 | +$24.30 |
| Q1 2026 | -$17.33 | +$55.77 |
| Q4 2025 | -$17.30 | +$84.62 |
| Q3 2025 | -$21.29 | +$73.36 |
| Q2 2025 | -$41.31 | +$30.69 |
| Q1 2025 | -$73.10 | -$34.30 |
| Q4 2024 | -$101.92 | -$96.32 |
CTEV is still losing money, but far less than before: $16.42 per share over the past year, against $101.92 at its worst in late 2024.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CTEV on earnings quality, reporting a profit while its opponent remains loss making.
CTEV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $268.3M | +9.1% |
| Q2 2026 | $257.5M | +6.6% |
| Q1 2026 | $244.7M | +5.8% |
| Q4 2025 | $246.6M | +6.2% |
| Q3 2025 | $246M | +6.7% |
| Q2 2025 | $241.6M | +3.5% |
| Q1 2025 | $231.3M | -1.4% |
| Q4 2024 | $232.1M | -4.9% |
CTEV's revenue has grown year over year for six quarters in a row: $268M last quarter, up 9.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.7% | +3.6 points |
| Q2 2026 | 9.1% | +2.2 points |
| Q1 2026 | 2.7% | -1.5 points |
| Q4 2025 | -3.1% | +15 points |
| Q3 2025 | 4.1% | +151 points |
| Q2 2025 | 6.9% | +231 points |
| Q1 2025 | 4.2% | +212 points |
| Q4 2024 | -18% | -35 points |
CTEV's operating margin was 7.7% last quarter, up 3.6 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CTEV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CTEV on profitability, with a higher operating margin.
CTEV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26.2M | -$9.9M |
| Q2 2026 | $54.6M | +49% |
| Q1 2026 | -$92.5M | -$23.6M |
| Q4 2025 | $36.4M | +$100.2M |
| Q3 2025 | -$16.3M | -140% |
| Q2 2025 | $36.6M | +$43.6M |
| Q1 2025 | -$68.9M | -459% |
| Q4 2024 | -$63.8M | -$60.2M |
CTEV's free cash flow was −$28M over the past year, against −$113M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CTEV on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTEV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +10.3K shares |
| 1 year | +3% | +495K shares |
| 3 years | +5% | +814K shares |
| 5 years | +4% | +653K shares |
| Available history | +562% | +14.4M shares |
CTEV has 17M diluted shares, up 3% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CTEV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CTEV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 9.4x | High |
| Q2 2026 | 9.6x | High |
| Q1 2026 | 9.7x | High |
| Q4 2025 | 9.6x | High |
| Q3 2025 | 10.3x | High |
| Q2 2025 | 52.3x | High |
| Q1 2024 | 85.5x | High |
| Q4 2023 | 7.7x | High |
CTEV's net debt is about 9.4 years of its operating earnings (EBITDA), down from 10 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over CTEV on leverage, with a lower net debt burden relative to earnings.
CTEV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.9 | Neutral |
| Stochastic | 21.6 | Neutral |
CTEV's weekly RSI is 49 (neutral) and its Stochastic is 22 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CTEV PE vs Healthcare Sector
| Metric | CTEV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CTEV has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CTEV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.9 | 13% above |
| 20 week MA | $29.1 | 7.6% below |
| 50 week MA | $26.9 | 0.1% below |
| 100 week MA | $32.3 | 17% below |
| 200 week MA | $36.3 | 26% below |
CTEV has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 26% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CTEV on trend strength, trading above more of its moving averages.
CTEV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $388.8 | $357.2 | -8.1% |
| 2021 | $357.2 | $176.8 | -51% |
| 2022 | $176.8 | $47.6 | -73% |
| 2023 | $47.6 | $57.6 | +21% |
| 2024 | $57.6 | $17.5 | -70% |
| 2025 | $17.5 | $42.0 | +140% |
| 2026 YTD | $42.0 | $26.9 | -36% |
CTEV's yearly returns have swung widely, from +140% in 2025 to −73% in 2022. It's down 36% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CTEV on returns for 2026, with the stronger performance.